Lumos Diagnostics Holdings (ASX:LDX) received an initial $767,800 purchase order from Phase Scientific for its FebriDx blood test, satisfying part of the year one minimum order quantity commitment under a distribution agreement with Phase Scientific, according to a Tuesday Australian bourse filing.
The order is associated with the $5 million prepayment milestone received by Lumos following the grant of the CLIA waiver for FebriDx by the US Food and Drug Administration on March 27.
Product delivery is expected to be fulfilled progressively between Tuesday and October.
The company's shares climbed nearly 7% in recent trading on Tuesday.